Updated June 2026 · ClinicalTrials.gov
Jiangsu HengRui Medicine Co., Ltd.
6 clinical trials · 6 recruiting · INDUSTRY
Jiangsu HengRui Medicine Co., Ltd. has 6 clinical trials registered on ClinicalTrials.gov, with 6 actively recruiting participants. The trials listed below cover 6 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.
About Jiangsu HengRui Medicine Co., Ltd.\'s Trial Portfolio
Jiangsu HengRui Medicine Co., Ltd. is an industry sponsor — typically a pharmaceutical, biotechnology, or medical device company. Industry sponsors fund and run the largest share of registered trials in the United States and are subject to FDA registration requirements under the FDA Amendments Act (FDAAA 801) for most drug and device studies.
6 of Jiangsu HengRui Medicine Co., Ltd.'s 6 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.
Jiangsu HengRui Medicine Co., Ltd.'s research footprint spans relapsed-refractory-ptclt-with-at-least-one-line-of-prior-systemic-therapy (1 trials), her2-positive-advanced-gastric-cancer-or-gastroesophageal-junction-adenocarcinoma (1), and recurrent-or-metastatic-cervical-cancer (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.
Jiangsu HengRui Medicine Co., Ltd.'s portfolio is weighted toward later-stage research — Phase 3 accounts for 50% of registered trials. Later-stage trials are the ones most likely to lead directly to FDA approval decisions, and they typically enroll the largest patient cohorts.
Trials by Jiangsu HengRui Medicine Co., Ltd.
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
This study was designed to compare the efficacy and safety of SHR2554 with Chidamide in patients with relapsed/refractory PTCL.
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression...
This study will assess the efficacy and safety of SHR-A1811 compared with treatment chosen by the investigator in participants with HER2-positive (defined as immunohistochemistry...
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
This study is a single-arm, multicenter Phase II clinical trial of SHR-A1811 for injection in patients with HER2-expressing recurrent or metastatic cervical cancer who have failed...
The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and...
SHR4640 tablets is a highly selective and potent URAT1 inhibitors. The study is being conducted to evaluate the efficacy, and safety of SHR4640 tablet combined with 40 mg/d...
Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis
Studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of RSS0343 tablets in patients with non-cystic fibrosis bronchiectasis
A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
The purpose of this study is to evaluate the efficacy and safety of HRS-8427 in patients with complicated urinary tract infection, including acute pyelonephritis.
How to Approach a Trial Listing
Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.
Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.
Authoritative Resources
Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.
Frequently Asked Questions
How many clinical trials does Jiangsu HengRui Medicine Co., Ltd. have on ClinicalTrials.gov?
Jiangsu HengRui Medicine Co., Ltd. has 6 clinical trials registered on the federal ClinicalTrials.gov registry, of which 6 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.
What conditions does Jiangsu HengRui Medicine Co., Ltd. study?
Jiangsu HengRui Medicine Co., Ltd.'s registered trials cover 6 conditions on ClinicalTrials.gov, led by relapsed-refractory-ptclt-with-at-least-one-line-of-prior-systemic-therapy (1 trial), her2-positive-advanced-gastric-cancer-or-gastroesophageal-junction-adenocarcinoma (1 trial), recurrent-or-metastatic-cervical-cancer (1 trial), primary-gout-and-hyperuricemia (1 trial), adolescent-asthma (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.
How do I join a Jiangsu HengRui Medicine Co., Ltd. clinical trial?
Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.
What does the trial phase mean?
Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.
Where does this trial data come from?
All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.
How This Sponsor Page Is Built
Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.
Other Trial Sponsors
87 trials · 87 recruiting
58 trials · 58 recruiting
48 trials · 48 recruiting
48 trials · 48 recruiting
48 trials · 48 recruiting
47 trials · 47 recruiting
Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."
Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.
Last updated 2026-06-26 · 6 trials tracked for Jiangsu HengRui Medicine Co., Ltd..